Medical Update: HER2-Positive Metastatic Breast Cancer

Medical Update: HER2-Positive Metastatic Breast Cancer
Rebecca J. Jaslow, MD
Clinical Assistant Professor, Medical Oncology
Thomas Jefferson University

About 20 percent of breast cancers are HER2 positive, or test positive for a protein called human epidermal growth factor receptor 2, or HER2. In this session from our 2019 Conference on Metastatic Breast Cancer, Dr. Jaslow discusses the latest treatment options targeting HER2-positive metastatic breast cancer and research in the pipeline. Hear about side effects of treatments and barriers to getting targeted medicine, as well as ways to overcome those barriers.

 

More In Metastatic

Blog Stories October 5, 2015
Article August 19, 2015